Prey S - Search Results

1

Brief Communication: Lambert-Eaton Myasthenic Paraneoplastic Syndrome Associated With Merkel Cell Carcinoma Successfully Treated by Immune Checkpoint Inhibitors: 2 Cases.

Gra M, Pham-Ledard A, Gerard E, Dutriaux C, Beylot-Barry M, Duval F, Carla L, Soulages A, Prey S. Gra M, et al. Among authors: prey s. J Immunother. 2023 Sep 1;46(7):276-278. doi: 10.1097/CJI.0000000000000480. Epub 2023 Jun 19. J Immunother. 2023. PMID: 37326491 Review.

2

Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo.

Larsabal M, Marti A, Jacquemin C, Rambert J, Thiolat D, Dousset L, Taieb A, Dutriaux C, Prey S, Boniface K, Seneschal J. Larsabal M, et al. Among authors: prey s. J Am Acad Dermatol. 2017 May;76(5):863-870. doi: 10.1016/j.jaad.2016.10.044. Epub 2017 Jan 13. J Am Acad Dermatol. 2017. PMID: 28094061

3

An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients.

Rousset M, Titier K, Bouchet S, Dutriaux C, Pham-Ledard A, Prey S, Canal-Raffin M, Molimard M. Rousset M, et al. Among authors: prey s. Clin Chim Acta. 2017 Jul;470:8-13. doi: 10.1016/j.cca.2017.04.009. Epub 2017 Apr 12. Clin Chim Acta. 2017. PMID: 28412197

4

Trough dabrafenib plasma concentrations can predict occurrence of adverse events requiring dose reduction in metastatic melanoma.

Rousset M, Dutriaux C, Bosco-Lévy P, Prey S, Pham-Ledard A, Dousset L, Gérard E, Bouchet S, Canal-Raffin M, Titier K, Molimard M. Rousset M, et al. Among authors: prey s. Clin Chim Acta. 2017 Sep;472:26-29. doi: 10.1016/j.cca.2017.07.012. Epub 2017 Jul 12. Clin Chim Acta. 2017. PMID: 28709799

5

Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.

Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C, Dousset L, Pham-Ledard A, Prey S, Beylot-Barry M, Daste A, Gross-Goupil M, Lallier J, Ravaud A, Forcade E, Bannwarth B, Truchetet ME, Richez C, Mehsen N, Schaeverbeke T; FHU ACRONIM. Kostine M, et al. Among authors: prey s. Ann Rheum Dis. 2018 Mar;77(3):393-398. doi: 10.1136/annrheumdis-2017-212257. Epub 2017 Nov 16. Ann Rheum Dis. 2018. PMID: 29146737

6

Vitiligo-like lesions in patients receiving anti-programmed cell death-1 therapies are distinct from spontaneously occurring active vitiligo.

Boniface K, Dutriaux C, Prey S, Taieb A, Seneschal J. Boniface K, et al. Among authors: prey s. J Am Acad Dermatol. 2018 Jan;78(1):e17-e18. doi: 10.1016/j.jaad.2017.08.028. J Am Acad Dermatol. 2018. PMID: 29241800 No abstract available.

7

Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.

Dupuis F, Lamant L, Gerard E, Torossian N, Chaltiel L, Filleron T, Beylot-Barry M, Dutriaux C, Prey S, Gros A, Jullie ML, Meyer N, Vergier B. Dupuis F, et al. Among authors: prey s. Br J Cancer. 2018 Jul;119(2):193-199. doi: 10.1038/s41416-018-0168-9. Epub 2018 Jul 5. Br J Cancer. 2018. PMID: 29973670 Free PMC article.

8

Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80 years) treated with ipilimumab for metastatic melanoma.

Leroy V, Gerard E, Dutriaux C, Prey S, Gey A, Mertens C, Beylot-Barry M, Pham-Ledard A. Leroy V, et al. Among authors: prey s. Cancer Immunol Immunother. 2019 Apr;68(4):545-551. doi: 10.1007/s00262-019-02298-9. Epub 2019 Jan 19. Cancer Immunol Immunother. 2019. PMID: 30661086 Free PMC article.

9

Reintroduction of dabrafenib after previous vemurafenib-induced DRESS: Not always safe!

Luherne C, Darrigade AS, Dutriaux C, Prey S, Milpied B. Luherne C, et al. Among authors: prey s. JAAD Case Rep. 2019 Apr 28;5(5):422-423. doi: 10.1016/j.jdcr.2019.02.033. eCollection 2019 May. JAAD Case Rep. 2019. PMID: 31061867 Free PMC article. No abstract available.

10

Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey.

Lesage C, Longvert C, Prey S, Maanaoui S, Dréno B, Machet L, Zehou O, Kramkimel N, Jeudy G, Skowron F, Aubin F, Visseaux L, Mansard S, Dereure O, Lesage FX, Guillot B; French Group of Onco-Dermatology. Lesage C, et al. Among authors: prey s. J Immunother. 2019 Jun;42(5):175-179. doi: 10.1097/CJI.0000000000000268. J Immunother. 2019. PMID: 31090656

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

79 results

Search Page